Why the study?
Do single doses of atenolol and acebutolol alter plasma ANP levels at rest and during exercise in patients with coronary heart disease?
Do single doses of atenolol and acebutolol alter plasma ANP levels at rest and during exercise in patients with coronary heart disease?
Acebutolol increases resting plasma ANP levels, likely due to its intrinsic sympathomimetic activity, while both beta-blockers augment exercise-induced ANP release in patients with coronary heart disease.
Acebutolol may raise ANP via ISA in CHD; leaves open any clinical relevance pending larger studies.
Plasma atrial natriuretic peptide (ANP) was measured during dynamic exercise in 10 patients with coronary heart disease before and after single dose atenolol 50 mg and acebutolol 200 mg, respectively. Systolic blood pressure, heart rate and the rate-pressure product increased during exercise before and after beta-blockade, but levels were lower after beta-blockade. Plasma ANP levels at rest were unchanged after atenolol, but rose after acebutolol (p less than 0.01). During exercise plasma ANP increased significantly both before and after beta-blockade, but plasma ANP levels were higher after acebutolol at all workloads (p less than 0.05), whereas plasma ANP levels after atenolol were higher at 125 W exclusively (p less than 0.05). The augmented ANP levels during exercise after beta-blockade probably reflect catecholamine-stimulated ANP release, whereas the elevated plasma ANP levels after acebutolol at rest might be a beta-adrenoceptor-mediated ANP release due to the intrinsic sympathomimetic effect of acebutolol.
No takes yet. Share an insight, caveat, or question.
Keller et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: